This week, the overall grades of nine Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Spectrum Pharmaceuticals’ (NASDAQ:SPPI) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. Spectrum Pharmaceuticals is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology. As of Feb. 6, 2013, 45.3% of outstanding Spectrum Pharmaceuticals shares were held short. For a full analysis of SPPI stock, visit Portfolio Grader.
Anacor Pharmaceuticals’ (NASDAQ:ANAC) rating falls this week to an F (“strong sell”), down from last week’s D (“sell”). Anacor Pharmaceuticals focuses on discovering, developing, and commercializing small-molecule therapeutics derived from boron chemistry platform. The stock gets F’s in Cash Flow and Sales Growth. The stock price has dropped 27.7% over the past month, worse than the 2.3% increase the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of ANAC stock.
This is a rough week for GTx Inc. (NASDAQ:GTXI). The company’s rating falls to D from the previous week’s C. GTx discovers, develops, and commercializes therapeutics primarily related to the treatment of serious men’s health conditions. The stock gets F’s in Equity and Cash Flow. For a full analysis of GTXI stock, visit Portfolio Grader.
This week, Acorda Therapeutics’ (NASDAQ:ACOR) rating worsens to a D from the company’s C rating a week ago. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The stock gets F’s in Earnings Momentum and Sales Growth. The trailing PE Ratio for the stock is 34.00. To get an in-depth look at ACOR, get Portfolio Grader’s complete analysis of ACOR stock.
Momenta Pharmaceuticals (NASDAQ:MNTA) gets weaker ratings this week as last week’s D drops to an F. Momenta Pharmaceuticals is a biotechnology company. For more information, get Portfolio Grader’s complete analysis of MNTA stock.
Exelixis’ (NASDAQ:EXEL) rating weakens this week, dropping to an F versus last week’s D. Exelixisis a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The stock receives F’s in Earnings Growth, Earnings Momentum, and Equity. Margin Growth and Sales Growth also get F’s. As of Feb. 6, 2013, 20.8% of outstanding Exelixis shares were held short. For a full analysis of EXEL stock, visit Portfolio Grader.
The rating of Protalix BioTherapeutics (AMEX:PLX) declines this week from C to a D. Protalix BioTherapeutics is a biotechnology company that has developed plant cell culture technology and a bioreactor system. The stock also rates an F in Equity. To get an in-depth look at PLX, get Portfolio Grader’s complete analysis of PLX stock.
Immunogen Inc.’s (NASDAQ:IMGN) rating weakens this week, dropping to a D versus last week’s C. Immunogen develops pharmaceuticals, primarily for the treatment of cancer. The stock gets F’s in Equity and Sales Growth. For more information, get Portfolio Grader’s complete analysis of IMGN stock.
The rating of Curis Inc. (NASDAQ:CRIS) declines this week from a D to an F. Curis is a drug discovery and development company that engages in the research and development of cancer therapeutics. Wall Street appears to agree with the stock downgrade, with share prices dropping 11% over the past month. The stock has a trailing PE Ratio of 106.00. To get an in-depth look at CRIS, get Portfolio Grader’s complete analysis of CRIS stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.